Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.
costs and cost analysis
days absent from work
diabetes complications
diabetes mellitus
disability
insurance
longitudinal register data
sick leave
type 2
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
20
12
2019
revised:
20
04
2020
accepted:
20
04
2020
pubmed:
25
4
2020
medline:
25
6
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
To analyse days absent from work related to individual microvascular, macrovascular and other complications of type 2 diabetes (T2D) and to identify key drivers of absence. National health and socio-economic individual-level data were analysed for the years 1997 to 2016 for people with T2D, and age-, sex- and residential region-matched controls (5:1) using linkage to Swedish national administrative registers, based on personal identity numbers. Regression analyses accounting for individual-level clustering and education were estimated to obtain days absent by individual complications. Alternative analyses, for example, workforce indicator and age subgroups, were explored for robustness and comparison purposes. A total of 413 000 people with T2D aged <66 years, comprising 4.9 million person-years, was included. The crude proportion with any absence was higher among those with T2D compared to controls (47% vs. 26%) in the index year, and the median (IQR) number of days was higher (223 [77;359] vs. 196 [59;352]) if any absence. Regression analyses showed that complications per se were a key driver of days absent: stroke (+102 days); end-stage renal disease (+70 days); severe vision loss (+56 days); and angina pectoris, heart failure, and osteoarthritis (+53 days each). The alternative analyses showed similar levels of days absent and age subgroups differed in expected directions. This study provides evidence of the persisting impact on productivity from complications that supports continued efforts to reduce risk factors in T2D. Future studies on burden of disease and economic evaluations of new therapies and disease management may use this new set of complication-specific estimates to improve understanding of the value of reducing complications.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1586-1597Subventions
Organisme : Funding for this study was provided by Novo Nordisk A/S
Pays : International
Informations de copyright
© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-yearfollow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2018;61(12):2461-2498.
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.
Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-862.
Breton M-C, Guénette L, Amiche MA, Kayibanda J-F, Grégoire J-P, Moisan J. Burden of diabetes on the ability to work: a systematic review. Diabetes Care. 2013;36(3):740-749.
Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811-831.
Sattar N, Rawshani A, Franzen S. Response by Sattar et al to letters regarding article, "age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks". Circulation. 2019;140(16):e724-e725.
Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int. 2013;2013:8.
National Board of Health and Welfare (NBHW). The National Patient Register 2019. Accessed November 4, 2019; 2019.
National Board of Health and Welfare (NBHW). Läkemedelsregistret [National Prescribed Drugs Register]. Accessed November 4, 2019; 2019.
Statistics Sweden. Longitudinal integrated database for health insurance and labour market studies (LISA) 2019. Accessed November 22, 2019, 2019.
Kahm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41(5):971-978.
Kahm K, Laxy M, Schneider U, Holle R. Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: a large claims-based study in Germany. Pharmacoeconomics. 2019;37(1):63-74.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):831-841.
Adamsson Eryd S, Svensson AM, Franzén S, Eliasson B, Nilsson PM, Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med. 2017;34(3):411-418.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract. 2017;123:199-208.
Gerdtham UG, Clarke P, Hayes A, Gudbjornsdottir S. Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics. 2009;27(1):81-90.
Kiadaliri AA, Gerdtham U-G, Nilsson P, Eliasson B, Gudbjörnsdottir S, Carlsson KS. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS One. 2013;8(5):e62650.
Steineck I, Cederholm J, Eliasson B, et al; the Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234.
Stata Statistical Software: Release 15. [computer program]. College Station, TX: StataCorp LLC; 2017.
Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897-916.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl. 1):S90-S102.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41(2):255-323.
Lung TWC, Petrie D, Herman WH, et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care. 2014;37:2974-2981.
Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732.